370 related articles for article (PubMed ID: 29205786)
1. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.
Jensen L; Kupcova V; Arold G; Pettersson J; Hjerpsted JB
Diabetes Obes Metab; 2018 Apr; 20(4):998-1005. PubMed ID: 29205786
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.
Baekdal TA; Thomsen M; Kupčová V; Hansen CW; Anderson TW
J Clin Pharmacol; 2018 Oct; 58(10):1314-1323. PubMed ID: 29693715
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
Marbury TC; Flint A; Jacobsen JB; Derving Karsbøl J; Lasseter K
Clin Pharmacokinet; 2017 Nov; 56(11):1381-1390. PubMed ID: 28349386
[TBL] [Abstract][Full Text] [Related]
4. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
Ikushima I; Jensen L; Flint A; Nishida T; Zacho J; Irie S
Adv Ther; 2018 Apr; 35(4):531-544. PubMed ID: 29536338
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.
Granhall C; Søndergaard FL; Thomsen M; Anderson TW
Clin Pharmacokinet; 2018 Dec; 57(12):1571-1580. PubMed ID: 29623579
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
11. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.
Shi A; Xie P; Nielsen LL; Skjøth TV; He X; Haugaard SP
Adv Ther; 2021 Jan; 38(1):550-561. PubMed ID: 33159658
[TBL] [Abstract][Full Text] [Related]
14. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
[TBL] [Abstract][Full Text] [Related]
15. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
16. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
Bækdal TA; Breitschaft A; Navarria A; Hansen CW
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):869-877. PubMed ID: 29897249
[TBL] [Abstract][Full Text] [Related]
17. Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.
Mosenzon O; Miller EM; Warren ML
Postgrad Med; 2020 Nov; 132(sup2):37-47. PubMed ID: 32815439
[TBL] [Abstract][Full Text] [Related]
18. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
19. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
Mann JFE; Hansen T; Idorn T; Leiter LA; Marso SP; Rossing P; Seufert J; Tadayon S; Vilsbøll T
Lancet Diabetes Endocrinol; 2020 Nov; 8(11):880-893. PubMed ID: 32971040
[TBL] [Abstract][Full Text] [Related]
20. Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.
Meier JJ; Granhall C; Hoevelmann U; Navarria A; Plum-Moerschel L; Ramesh C; Tannapfel A; Kapitza C
Diabetes Obes Metab; 2022 Apr; 24(4):684-692. PubMed ID: 34957654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
